Skip to main content

Table 1 Patients’ characteristics

From: Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity

 

Excluded from randomized controlled trial (N = 295)

Included in randomized controlled trial (N = 406)

P value

Demographics and background

 Age (Mean ± SD), year

65 ± 18

66 ± 17

0.411

 Gender (female)

101 (34.2%)

151 (37.2%)

0.421

 Country

  

0.000

  Israel

274 (92.9%)

270 (66.5%)

 

  Greece

16 (5.4%)

76 (18.7%)

 

  Italy

5 (1.7%)

60 (14.8%)

 

 Admitted from home

204 (69.2%)

276 (68%)

0.742

 BMI, kg/m2

27.1 (6.7)

27.4 (5.8)

0.610

 Charlson Score (Mean ± SD)

2 ± 2

2 ± 2

0.497

 Dementia

17 (5.8%)

49 (10.7%)

0.050

 Diabetes

61 (20.7%)

90 (22.2%)

0.636

 Chronic kidney disease

71 (24.1%)

79 (19.5%)

0.129

 Hematological Malignancy

25 (8.5%)

14 (3.4%)

0.004

 Congestive heart failure

66 (22.4%)

92 (22.7%)

0.928

 Chronic pulmonary disease

57 (19.3%)

91 (22.4%)

0.322

 Immune suppressive therapy

54 (18.3%)

61 (15%)

0.247

 Known colonization by pathogen before infection

69 (23.4%)

96 (23.6%)

0.937

 Recent surgery

83 (28.1%)

114 (28.1%)

0.987

Status at infection onset (culture taken time)

 Temperature, °C (SD)

37.9 (1.7)

38.0 (1.7)

0.655

 Systolic blood pressure, mm Hg (SD)

106 (24)

109 (21)

0.054

 Haemodynamic support

68 (24.2%)

75 (18.5%)

0.069

 Mechanical ventilation (invasive)

198 (69.5%)

264 (65%)

0.221

 Haemodialysis

11 (3.9%)

27 (6.7%)

0.118

 SOFA score (Mean ± SD)

6 ± 3

6 ± 3

0.755

 Creatinine Clearance (Cockcroft-Gault Equation), mL/min (Percentiles 25–75)

59.79 (32.54–108.58)

69.95 (41.21–126.27)

0.012

 Albumin, g/dL (SD)

2.3 (0.6)

2.4 (0.7)

0.285

 White blood cells, thousands/mL (SD)

13.22 (9.85)

14.12 (8.89)

0.212

 Arterial line

76 (25.8%)

151 (37.2%)

0.001

 Central venous catheter

119 (40.3%)

225 (55.4%)

0.000

 Urinary catheter

228 (77.3%)

354 (87.2%)

0.001

 Nasogastric tube

201 (68.1%)

285 (70.2%)

0.559